World Alzheimer’s Day is observed on 21 September every year. This
trend is aimed at drawing public’s attention towards the problem of such
socially significant disease as acquired dementia, which affects a vast
number of able-bodied elderly people in different countries. Today
dementia can truly be called “the plague of the 21st century”; according
to the WHO, currently 35.6 million people are living with dementia
across the world. This figure is expected to double by 2030, reaching
65.7 million, and more than triple by 2050, exceeding 115 million
people. Average life expectancy with this disease is 8-10 years.
According to experts, the total number of people with Alzheimer’s
disease in Russia may be approximately of 1.8 million.
Dementia (Latin: Dementia, madness) is acquired mental retardation,
persistent reduction of cognitive activity with loss of acquired
knowledge and practical experience and the difficulty or impossibility
of acquiring new ones. The disease is manifested by problems with
memory, impaired judgment, language, orientation, communication, and
executive functions. These most common symptoms are more often occur in
the elderly. Epidemiological data show that rate of dementia is at least
10% in the age group of 65-75 years and from 15 to 20% in the age group
of 80 years and above.
It’s no coincidence that GEROPHARM turned to the issue of dementia.
Neurology is one of priorities for the group of companies. GEROPHARM’s
portfolio includes original drugs Cortexin (effective neuroprotector)
and Cortexin for children (dosage form for children). Levetinol
(effective antiepileptic agent) entered the market in 2013. In pursuit
of its consistent policy of expanding the portfolio in existing product
lines, the company began to produce another drug in this line:
Memantinol, a modern medicine for the treatment of moderate to severe
Alzheimer’s type dementia. The drug improves cognitive processes and
increases daily activity. Memantinol enters the Russian market with the
slogan “Dementia: not a reason for refreshing.”
The company is planning to present the drug to the medical community
on the 21st of September, a landmark date for the worldwide fight
against Alzheimer’s disease.
Today, the awareness about dementia among Russian citizens is
unfortunately far from the scale of the problem. Many families which
faced the first symptoms of the disease in a loved one (forgetfulness,
untidiness, loss of interest in life) attribute them to the natural
aging process and only visit a doctor when the disease gets worse.
Meanwhile, a timely therapy allows to delay all unpleasant effects which
reduce the quality of life of patients and their relatives for several
For several years now, GEROPHARM’s active outreach and
awareness-raising efforts have supplemented its mainstream activities in
the field of development and production of modern pharmaceuticals. The
company annually initiates activities and joins global initiatives aimed
at raising public awareness about preventive measures of socially
significant diseases and assistance in the rehabilitation and
socialization of people with neurological diseases. Release of the new
neurological drug and dementia awareness rising is another important
step to be taken by the company in the direction of improving the
quality of life of people.
World Alzheimer’s Day is observed every year since 1994 on the initiative of the Alzheimer Disease International (ADI).
Alois Alzheimer (14 June 1864, Marktbreit, Germany) is a German
psychiatrist and neuropathologist, author of numerous articles
concerning such issues as alcoholic psychosis, schizophrenia, epilepsy,
cerebral syphilis, Huntington’s chorea, arteriosclerotic brain atrophy
(1894), presenile psychosis (1907). He received a medical degree in
Würzburg and subsequently lived and worked in Frankfurt.
Alzheimer made a significant contribution to the research of nervous system disorders. His research of senile dementia which later became known as Alzheimer’s disease immortalized his name. Relying on the results of his own fundamental research, Alzheimer described the main differences between vascular and neurodegenerative dementias. German psychiatrist Emil Kraepelin, a colleague of Alzheimer, later named a type of senile dementia after Alzheimer.